证券代码：000766 证券简称：通化金马 公告编号：2026-3 通化金马药业集团股份有限公司 关于召开 2026 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 一、召开会议的基本情况 1、股东会届次：2026 年第一次临时股东会 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2026 年 03 月 09 日 7、出席对象： （1）在股权登记日持有公司股份的普通股股东或其代理人； 于股权登记日下午收市时在中国结算深圳分公司登记在册的公司全体普通股股东均有 权出席股东会，并可以以书面形式委托代理人出席会议和参加表决，该股东代理人不必是 本公司股东。 （2）公司董事和高级管理人员； 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市 规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法 律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2026 年 03 月 16 日 14:30 ...

证券代码：000766 证券简称：通化金马 公告编号：2026-1 通化金马药业集团股份有限公司 第十一届董事会 2026 年第一次临时会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1.通化金马药业集团股份有限公司第十一届董事会2026年第一次临时会议通知 于2026年2月26日以微信和电子邮件形式送达全体董事。 2.2026 年 2 月 27 日上午 9 时 30 分以现场和通讯方式召开。 3.会议应到董事9人，实到董事9人。 4.会议由董事长张玉富先生主持，部分高管人员列席了本次会议。 5.本次董事会会议的召开符合有关法律、行政法规、部门规章、规范性文件和 公司章程的规定。 为满足公司生产经营和发展的需要，公司拟向银行申请不超过11,000.00万元的 信用贷款，贷款期限一年。其中：公司拟向吉林农村商业银行股份有限公司通化东 华路支行申请最高额不超过5,500.00万元的信用贷款；拟向广发银行股份有限公司 长春分行申请最高额不超过5,500.00万元的信用贷款。 董事会授权经营层全权办理本次贷款及相关事项申请事宜并签 ...

证券日报网讯 2月26日，通化金马在互动平台回答投资者提问时表示，公司2025年度经营业绩将在2025 年度报告中披露，请投资者关注公司公告。 （文章来源：证券日报） ...

Core Viewpoint - The report highlights the growth in the chemical raw materials and products manufacturing industry in China, indicating a positive trend in the number of enterprises and overall market potential from 2026 to 2032 [1] Industry Summary - As of January to December 2025, the number of enterprises in the chemical raw materials and products manufacturing industry reached 27,102, an increase of 815 compared to the previous year, representing a year-on-year growth of 3.1% [1] - This sector accounts for 5.15% of the total industrial enterprises in China, reflecting its significance within the broader industrial landscape [1] - The report is based on data from the National Bureau of Statistics and compiled by Zhiyan Consulting, a leading industry consulting firm in China [1] Company Summary - The report mentions several listed companies in the chemical sector, including Hainan Haiyao (000566), Northeast Pharmaceutical (000597), and others, indicating a diverse range of players in the market [1] - Zhiyan Consulting provides comprehensive industry research reports, business plans, feasibility studies, and customized services, emphasizing its role in supporting investment decisions in the chemical industry [1]

Core Viewpoint - Tonghua Golden Horse has made significant progress in the development of its new chemical drug, Amber Dihydroaminoacridine Tablets, which has completed comprehensive review work and is now in the final review stage, marking it as a noteworthy event in the near term [2] Financial Performance - For the third quarter of 2025, the company reported revenue of 892 million yuan and a net profit attributable to shareholders of 24.96 million yuan [2]

Group 1 - The core point of the article is that Tonghua Golden Horse (000766) has completed the comprehensive review of its Class 1 chemical new drug, Amber Dihydroaminoacridine Tablets, and is now in the final review stage, which is a significant development to watch [1] Group 2 - The company reported its financial performance based on the Q3 2025 data, showing revenue of 892 million yuan and a net profit attributable to shareholders of 24.96 million yuan [2]

Group 1 - The company, Tonghua Golden Horse, has indicated that it will disclose significant information regarding the review of its new drug, Amber Dihydroaminoacridine Tablets, through designated information disclosure media [2] - Investors are advised to pay attention to the company's announcements for updates on the drug's market application review process [2]

Group 1 - The company Tonghua Golden Horse (000766.SZ) has completed the comprehensive review of its chemical Class 1 new drug, Amber Dihydroaminoacridine Tablets, and has provided the required professional research materials, entering the final review stage [2] - The progress of all related work for the new drug is reported to be normal [2] - The company will disclose any significant information regarding the new drug through designated information disclosure media, urging investors to pay attention to company announcements [2]

Group 1 - The company Tonghua Golden Horse (000766) will disclose the number of shareholders at specific reporting periods in its regular reports [1]

Group 1 - The core point of the article is that Tonghua Golden Horse has completed the comprehensive review of its new chemical drug, Amber Tetrahydroaminoacridine Tablets, and is now in the final review stage [2] - The company has provided all required professional research materials as part of the review process [2] - The company will disclose any significant information regarding the new drug through designated information disclosure media, urging investors to pay attention to company announcements [2]